Green Cross Lab Cell Corporation
GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC. GC Cell Corporation has strategic agreement with Lukas Biomedical Co., Ltd. to develop Cell therapy. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in Nove… Read more
Green Cross Lab Cell Corporation (144510) - Total Assets
Latest total assets as of September 2025: ₩565.79 Billion KRW
Based on the latest financial reports, Green Cross Lab Cell Corporation (144510) holds total assets worth ₩565.79 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Green Cross Lab Cell Corporation - Total Assets Trend (2015–2024)
This chart illustrates how Green Cross Lab Cell Corporation’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Green Cross Lab Cell Corporation - Asset Composition Analysis
Current Asset Composition (December 2024)
Green Cross Lab Cell Corporation's total assets of ₩565.79 Billion consist of 7.3% current assets and 92.7% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩-9.81K | 0.9% |
| Accounts Receivable | ₩19.50 Billion | 3.4% |
| Inventory | ₩8.94 Billion | 1.6% |
| Property, Plant & Equipment | ₩109.57 Billion | 18.9% |
| Intangible Assets | ₩32.53 Billion | 5.6% |
| Goodwill | ₩330.81 Billion | 57.2% |
Asset Composition Trend (2015–2024)
This chart illustrates how Green Cross Lab Cell Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Green Cross Lab Cell Corporation's current assets represent 7.3% of total assets in 2024, a decrease from 46.2% in 2015.
- Cash Position: Cash and equivalents constituted 0.9% of total assets in 2024, up from 0.3% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 62.0% of total assets, an increase from 14.0% in 2015.
- Asset Diversification: The largest asset category is goodwill at 57.2% of total assets.
Green Cross Lab Cell Corporation Competitors by Total Assets
Key competitors of Green Cross Lab Cell Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Optipharm.CO.LTD
KQ:153710
|
Korea | ₩42.32 Billion |
Green Cross Lab Cell Corporation - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Green Cross Lab Cell Corporation generates 0.30x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Green Cross Lab Cell Corporation is currently not profitable relative to its asset base.
Green Cross Lab Cell Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.60 | 0.65 | 1.52 |
| Quick Ratio | 0.52 | 0.55 | 1.49 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩-38.84 Billion | ₩ -32.33 Billion | ₩ 8.81 Billion |
Green Cross Lab Cell Corporation - Advanced Valuation Insights
This section examines the relationship between Green Cross Lab Cell Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.86 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -13.1% |
| Total Assets | ₩578.35 Billion |
| Market Capitalization | $147.96 Million USD |
Valuation Analysis
Below Book Valuation: The market values Green Cross Lab Cell Corporation's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Green Cross Lab Cell Corporation's assets decreased by 13.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Green Cross Lab Cell Corporation (2015–2024)
The table below shows the annual total assets of Green Cross Lab Cell Corporation from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩578.35 Billion | -13.05% |
| 2023-12-31 | ₩665.17 Billion | -1.68% |
| 2022-12-31 | ₩676.53 Billion | +4.80% |
| 2021-12-31 | ₩645.57 Billion | +745.41% |
| 2020-12-31 | ₩76.36 Billion | +12.19% |
| 2019-12-31 | ₩68.06 Billion | +18.85% |
| 2018-12-31 | ₩57.27 Billion | +3.45% |
| 2017-12-31 | ₩55.36 Billion | +1.54% |
| 2016-12-31 | ₩54.51 Billion | +223.28% |
| 2015-12-31 | ₩16.86 Billion | -- |